The global brucellosis vaccines market size is calculated at USD 266.78 million in 2025 and is forecasted to reach around USD 406.94 million by 2034, accelerating at a CAGR of 4.81% from 2025 to 2034. The North America brucellosis vaccines market size surpassed USD 109.42 million in 2024 and is expanding at a CAGR of 4.93% during the forecast period. The market sizing and forecasts are revenue-based (USD Million/Billion), with 2024 as the base year.
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
3.1. Market Snapshot
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
5.1. COVID-19 Landscape: Brucellosis Vaccines Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
8.1. Brucellosis Vaccines Market Revenue and Volume Forecast, by Type
8.1.1. Rbs1 Vaccine
8.1.1.1. Market Revenue and Volume Forecast
8.1.2. S19 Vaccine
8.1.2.1. Market Revenue and Volume Forecast
8.1.3. Others
8.1.3.1. Market Revenue and Volume Forecast
9.1. Brucellosis Vaccines Market Revenue and Volume Forecast, by Vaccine
9.1.1. DNA Vaccine
9.1.1.1. Market Revenue and Volume Forecast
9.1.2. Subunit Vaccine
9.1.2.1. Market Revenue and Volume Forecast
9.1.3. Vector Vaccine
9.1.3.1. Market Revenue and Volume Forecast
9.1.4. Recombinant Vaccine
9.1.4.1. Market Revenue and Volume Forecast
10.1. Brucellosis Vaccines Market Revenue and Volume Forecast, by Application
10.1.1. Cattle
10.1.1.1. Market Revenue and Volume Forecast
10.1.2. Sheep & Goat
10.1.2.1. Market Revenue and Volume Forecast
10.1.3. Others
10.1.3.1. Market Revenue and Volume Forecast
11.1. Brucellosis Vaccines Market Revenue and Volume Forecast, by Distribution Channel
11.1.1. Veterinary Hospitals & Clinics
11.1.1.1. Market Revenue and Volume Forecast
11.1.2. Retail Channels
11.1.2.1. Market Revenue and Volume Forecast
11.1.3. Public
11.1.3.1. Market Revenue and Volume Forecast
12.1. North America
12.1.1. Market Revenue and Volume Forecast, by Type
12.1.2. Market Revenue and Volume Forecast, by Vaccine
12.1.3. Market Revenue and Volume Forecast, by Application
12.1.4. Market Revenue and Volume Forecast, by Distribution Channel
12.1.5. U.S.
12.1.5.1. Market Revenue and Volume Forecast, by Type
12.1.5.2. Market Revenue and Volume Forecast, by Vaccine
12.1.5.3. Market Revenue and Volume Forecast, by Application
12.1.5.4. Market Revenue and Volume Forecast, by Distribution Channel
12.1.6. Rest of North America
12.1.6.1. Market Revenue and Volume Forecast, by Type
12.1.6.2. Market Revenue and Volume Forecast, by Vaccine
12.1.6.3. Market Revenue and Volume Forecast, by Application
12.1.6.4. Market Revenue and Volume Forecast, by Distribution Channel
12.2. Europe
12.2.1. Market Revenue and Volume Forecast, by Type
12.2.2. Market Revenue and Volume Forecast, by Vaccine
12.2.3. Market Revenue and Volume Forecast, by Application
12.2.4. Market Revenue and Volume Forecast, by Distribution Channel
12.2.5. UK
12.2.5.1. Market Revenue and Volume Forecast, by Type
12.2.5.2. Market Revenue and Volume Forecast, by Vaccine
12.2.5.3. Market Revenue and Volume Forecast, by Application
12.2.5.4. Market Revenue and Volume Forecast, by Distribution Channel
12.2.6. Germany
12.2.6.1. Market Revenue and Volume Forecast, by Type
12.2.6.2. Market Revenue and Volume Forecast, by Vaccine
12.2.6.3. Market Revenue and Volume Forecast, by Application
12.2.6.4. Market Revenue and Volume Forecast, by Distribution Channel
12.2.7. France
12.2.7.1. Market Revenue and Volume Forecast, by Type
12.2.7.2. Market Revenue and Volume Forecast, by Vaccine
12.2.7.3. Market Revenue and Volume Forecast, by Application
12.2.7.4. Market Revenue and Volume Forecast, by Distribution Channel
12.2.8. Rest of Europe
12.2.8.1. Market Revenue and Volume Forecast, by Type
12.2.8.2. Market Revenue and Volume Forecast, by Vaccine
12.2.8.3. Market Revenue and Volume Forecast, by Application
12.2.8.4. Market Revenue and Volume Forecast, by Distribution Channel
12.3. APAC
12.3.1. Market Revenue and Volume Forecast, by Type
12.3.2. Market Revenue and Volume Forecast, by Vaccine
12.3.3. Market Revenue and Volume Forecast, by Application
12.3.4. Market Revenue and Volume Forecast, by Distribution Channel
12.3.5. India
12.3.5.1. Market Revenue and Volume Forecast, by Type
12.3.5.2. Market Revenue and Volume Forecast, by Vaccine
12.3.5.3. Market Revenue and Volume Forecast, by Application
12.3.5.4. Market Revenue and Volume Forecast, by Distribution Channel
12.3.6. China
12.3.6.1. Market Revenue and Volume Forecast, by Type
12.3.6.2. Market Revenue and Volume Forecast, by Vaccine
12.3.6.3. Market Revenue and Volume Forecast, by Application
12.3.6.4. Market Revenue and Volume Forecast, by Distribution Channel
12.3.7. Japan
12.3.7.1. Market Revenue and Volume Forecast, by Type
12.3.7.2. Market Revenue and Volume Forecast, by Vaccine
12.3.7.3. Market Revenue and Volume Forecast, by Application
12.3.7.4. Market Revenue and Volume Forecast, by Distribution Channel
12.3.8. Rest of APAC
12.3.8.1. Market Revenue and Volume Forecast, by Type
12.3.8.2. Market Revenue and Volume Forecast, by Vaccine
12.3.8.3. Market Revenue and Volume Forecast, by Application
12.3.8.4. Market Revenue and Volume Forecast, by Distribution Channel
12.4. MEA
12.4.1. Market Revenue and Volume Forecast, by Type
12.4.2. Market Revenue and Volume Forecast, by Vaccine
12.4.3. Market Revenue and Volume Forecast, by Application
12.4.4. Market Revenue and Volume Forecast, by Distribution Channel
12.4.5. GCC
12.4.5.1. Market Revenue and Volume Forecast, by Type
12.4.5.2. Market Revenue and Volume Forecast, by Vaccine
12.4.5.3. Market Revenue and Volume Forecast, by Application
12.4.5.4. Market Revenue and Volume Forecast, by Distribution Channel
12.4.6. North Africa
12.4.6.1. Market Revenue and Volume Forecast, by Type
12.4.6.2. Market Revenue and Volume Forecast, by Vaccine
12.4.6.3. Market Revenue and Volume Forecast, by Application
12.4.6.4. Market Revenue and Volume Forecast, by Distribution Channel
12.4.7. South Africa
12.4.7.1. Market Revenue and Volume Forecast, by Type
12.4.7.2. Market Revenue and Volume Forecast, by Vaccine
12.4.7.3. Market Revenue and Volume Forecast, by Application
12.4.7.4. Market Revenue and Volume Forecast, by Distribution Channel
12.4.8. Rest of MEA
12.4.8.1. Market Revenue and Volume Forecast, by Type
12.4.8.2. Market Revenue and Volume Forecast, by Vaccine
12.4.8.3. Market Revenue and Volume Forecast, by Application
12.4.8.4. Market Revenue and Volume Forecast, by Distribution Channel
12.5. Latin America
12.5.1. Market Revenue and Volume Forecast, by Type
12.5.2. Market Revenue and Volume Forecast, by Vaccine
12.5.3. Market Revenue and Volume Forecast, by Application
12.5.4. Market Revenue and Volume Forecast, by Distribution Channel
12.5.5. Brazil
12.5.5.1. Market Revenue and Volume Forecast, by Type
12.5.5.2. Market Revenue and Volume Forecast, by Vaccine
12.5.5.3. Market Revenue and Volume Forecast, by Application
12.5.5.4. Market Revenue and Volume Forecast, by Distribution Channel
12.5.6. Rest of LATAM
12.5.6.1. Market Revenue and Volume Forecast, by Type
12.5.6.2. Market Revenue and Volume Forecast, by Vaccine
12.5.6.3. Market Revenue and Volume Forecast, by Application
12.5.6.4. Market Revenue and Volume Forecast, by Distribution Channel
13.1. Merck & Co.
13.1.1. Company Overview
13.1.2. Product Offerings
13.1.3. Financial Performance
13.1.4. Recent Initiatives
13.2. CZ Vaccines
13.2.1. Company Overview
13.2.2. Product Offerings
13.2.3. Financial Performance
13.2.4. Recent Initiatives
13.3. Colorado Serum Company
13.3.1. Company Overview
13.3.2. Product Offerings
13.3.3. Financial Performance
13.3.4. Recent Initiatives
13.4. Indian Immunologicals
13.4.1. Company Overview
13.4.2. Product Offerings
13.4.3. Financial Performance
13.4.4. Recent Initiatives
13.5. Hester Biosciences
13.5.1. Company Overview
13.5.2. Product Offerings
13.5.3. Financial Performance
13.5.4. Recent Initiatives
13.6. Veterinary Technologies Corporation
13.6.1. Company Overview
13.6.2. Product Offerings
13.6.3. Financial Performance
13.6.4. Recent Initiatives
13.7. Laboratorios Tornel
13.7.1. Company Overview
13.7.2. Product Offerings
13.7.3. Financial Performance
13.7.4. Recent Initiatives
13.8. Five Animal Health
13.8.1. Company Overview
13.8.2. Product Offerings
13.8.3. Financial Performance
13.8.4. Recent Initiatives
13.9. VETAL Animal Health Products Inc.
13.9.1. Company Overview
13.9.2. Product Offerings
13.9.3. Financial Performance
13.9.4. Recent Initiatives
14.1. Primary Research
14.2. Secondary Research
14.3. Assumptions
15.1. About Us
15.2. Glossary of Terms
For questions or customization requests, please reach out to us at sales@precedenceresearch.com
Plan your call and get expert insights!
Schedule a Meeting
No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client
Report Description
Get a Sample